Skip to main content

Whole brain reirradiation and concurrent temozolomide in patients with brain metastases

Journal of Neuro-Oncology volume 118, pages 329–334 (2014)Cite this article

Abstract

A second course of whole brain radiation therapy (WBRT) has been employed in selected patients with progressive brain metastases providing favorable symptomatic palliation with acceptable toxicity, although its efficacy and safety remain matter of debate. In the present study we have evaluated the outcomes in patients with progressive intracranial disease treated with WBRT reirradiation and concurrent temozolomide between October 2010 and May 2013. Data were obtained from a prospectively maintained database including patients with brain tumors treated with radiotherapy at Sant’Andrea Hospital. We identified 27 patients (10 males and 17 females) with a median age of 54 years who received WBRT reirradiation at a dose of 25 Gy in ten fractions plus concomitant daily temozolomide administered orally at a dose of 75 mg/m2. At the time of repeat WBRT all patients had a KPS ≥ 60. The primary disease sites were lung (n = 18) and breast (n = 9). The median overall survival after the second course of WBRT was 6.2 months and the median time to progression was 5.5 months. Eight patients experienced complete resolution of symptoms, 9 patients had a significant improvement, and 6 patients had no change in their neurologic function. Four patients had further deterioration after reirradiation. Overall, 85 % of patients improved or maintained their neurologic status. No severe acute toxicity during or after the second course of WBRT reirradiation was observed. On multivariate analysis with the Cox proportional hazards model, stable or absent extracranial metastases (p = 0.005) and response to treatment (p = 0.01) were independent favorable prognostic factors for survival. The median and 12-month survival rates were 12 months and 50 % in patients with stable or absent extracranial disease and 4.6 months and 7 % in those with progressive extracranial disease (p = 0.001). In conclusion, in the respect to the small number of treated patients, repeat WBRT plus concomitant temozolomide may be a treatment option in selected patients with multiple brain metastases to improve or maintain neurological conditions and quality of life with acceptable toxicity. The favorable effects of concomitant temozolomide on survival remain unclear.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

Fig. 1
Fig. 2

References

  1. Norden AD, Wen PY, Kesari S (2005) Brain metastases. Curr Opin Neurol 18:654–661

    PubMed  Google Scholar 

  2. Aoyama H, Shirato H, Tago M, Nakagawa K, Toyoda T, Hatano K, Kenjyo M, Oya N, Hirota S, Shioura H, Kunieda E, Inomata T, Hayakawa K, Katoh N, Kobashi G (2006) Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial. JAMA 295:2483–2491

    CAS  PubMed  Article  Google Scholar 

  3. Kocher M, Soffietti R, Abacioglu U, Villà S, Fauchon F, Baumert BG, Fariselli L, Tzuk-Shina T, Kortmann RD, Carrie C, Hassel MB, Kouri M, Valeinis E, van den Berge D, Collette S, Collette L, Mueller RP (2011) Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952–26001 study. J Clin Oncol 29:134–141

    PubMed Central  PubMed  Article  Google Scholar 

  4. Scoccianti S, Ricardi U (2012) Treatment of brain metastases: review of phase III randomized controlled trials. Radiother Oncol 102:168–179

    PubMed  Article  Google Scholar 

  5. Ammirati M, Cobbs CS, Linskey ME, Paleologos NA, Ryken TC, Burri SH, Asher AL, Loeffler JS, Robinson PD, Andrews DW, Gaspar LE, Kondziolka D, McDermott M, Mehta MP, Mikkelsen T, Olson JJ, Patchell RA, Kalkanis SN (2010) The role of retreatment in the management of recurrent/progressive brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol 96:85–96

    PubMed Central  PubMed  Article  Google Scholar 

  6. Shehata WM, Hendrickson FR, Hindo WA (1974) Rapid fractionation technique and re-treatment of cerebral metastases by irradiation. Cancer 34:257–261

    CAS  PubMed  Article  Google Scholar 

  7. Kurup P, Reddy S, Hendrickson FR (1980) Results of re-irradiation for cerebral metastases. Cancer 46:2587–2589

    CAS  PubMed  Article  Google Scholar 

  8. Hazuka MB, Kinzie JJ (1988) Brain metastases: results and effects of re-irradiation. Int J Radiat Oncol Biol Phys 15:433–437

    CAS  PubMed  Article  Google Scholar 

  9. Cooper JS, Steinfeld AD, Lerch IA (1990) Cerebral metastases: value of reirradiation in selected patients. Radiology 174:883–885

    CAS  PubMed  Google Scholar 

  10. Wong WW, Schild SE, Sawyer TE, Shaw EG (1996) Analysis of outcome in patients reirradiated for brain metastases. Int J Radiat Oncol Biol Phys 34:585–590

    CAS  PubMed  Article  Google Scholar 

  11. Abdel-Wahab MM, Wolfson AH, Raub W, Landy H, Feun L, Sridhar K, Brandon AH, Mahmood S, Markoe AM (1997) The role of hyperfractionated re-irradiation in metastatic brain disease: a single institutional trial. Am J Clin Oncol 20:158–160

    CAS  PubMed  Article  Google Scholar 

  12. Sadikov E, Bezjak A, Yi QL, Wells W, Dawson L, Millar BA, Laperriere N (2007) Value of whole brain re-irradiation for brain metastases—single centre experience. Clin Oncol (R Coll Radiol) 19:532–538

    CAS  Article  Google Scholar 

  13. Akiba T, Kunieda E, Kogawa A, Komatsu T, Tamai Y, Ohizumi Y (2012) Re-irradiation for metastatic brain tumors with whole-brain radiotherapy. Jpn J Clin Oncol 42:264–269

    PubMed  Article  Google Scholar 

  14. Son CH, Jimenez R, Niemierko A, Loeffler JS, Oh KS, Shih HA (2012) Outcomes after whole brain reirradiation in patients with brain metastases. Int J Radiat Oncol Biol Phys 82:167–172

    Article  Google Scholar 

  15. Ozgen Z, Atasoy BM, Ucuncu Kefeli A, Seker A, Dane F, Abacioglu U (2013) The benefit of whole brain reirradiation in patients with multiple brain metastases. Radiat Oncol 8:186

    PubMed Central  PubMed  Article  Google Scholar 

  16. Mehta MP, Paleologos NA, Mikkelsen T, Robinson PD, Ammirati M, Andrews DW, Asher AL, Burri SH, Cobbs CS, Gaspar LE, Kondziolka D, Linskey ME, Loeffler JS, McDermott M, Olson JJ, Patchell RA, Ryken TC, Kalkanis SN (2010) The role of chemotherapy in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol 96:71–83

    PubMed Central  PubMed  Article  Google Scholar 

  17. Antonadou D, Paraskevaidis M, Sarris G, Coliarakis N, Economou I, Karageorgis P, Throuvalas N (2002) Phase II randomized trial of temozolomide and concurrent radiotherapy in patients with brain metastases. J Clin Oncol 20:3644–3650

    CAS  PubMed  Article  Google Scholar 

  18. Verger E, Gil M, Yaya R, Viñolas N, Villà S, Pujol T, Quintó L, Graus F (2005) Temozolomide and concomitant whole brain radiotherapy in patients with brain metastases: a phase II randomized trial. Int J Radiat Oncol Biol Phys 61:185–191

    CAS  PubMed  Article  Google Scholar 

  19. Chua D, Krzakowski M, Chouaid C, Pallotta MG, Martinez JI, Gottfried M, Curran W, Throuvalas N (2010) Whole-brain radiation therapy plus concomitant temozolomide for the treatment of brain metastases from non-small-cell lung cancer: a randomized, open-label phase II study. Clin Lung Cancer 11:176–181

    CAS  PubMed  Article  Google Scholar 

  20. Gamboa-Vignolle C, Ferrari-Carballo T, Arrieta Ó, Mohar A (2012) Whole-brain irradiation with concomitant daily fixed-dose temozolomide for brain metastases treatment: a randomised phase II trial. Radiother Oncol 102:187–191

    CAS  PubMed  Article  Google Scholar 

  21. Chang JE, Khuntia D, Robins HI, Mehta MP (2007) Radiotherapy and radiosensitizers in the treatment of glioblastoma multiforme. Clin Adv Hematol Oncol 5:894–902

    PubMed  Google Scholar 

Download references

Conflict of interest

The authors declare that they have no conflict of interest.

Author information

Affiliations

  1. Unit of Radiation Oncology, Sant’Andrea Hospital, University Sapienza, Via di Grottarossa 1035, 00189, Rome, Italy

    Giuseppe Minniti, Claudia Scaringi, Vitaliana De Sanctis, Maurizio Valeriani, Mattia Osti & Riccardo Maurizi Enrici

  2. IRCCS Neuromed, 86077, Pozzilli, IS, Italy

    Giuseppe Minniti & Gaetano Lanzetta

  3. Unit of Neuroradiology, Sant’Andrea Hospital, University Sapienza, 00189, Rome, Italy

    Alessandro Bozzao

  4. Department of Radiology, IRCCS San Raffaele Pisana, Rome, Italy

    Andrea Romano

Authors
  1. Giuseppe Minniti
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Claudia Scaringi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Gaetano Lanzetta
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Alessandro Bozzao
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Andrea Romano
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Vitaliana De Sanctis
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Maurizio Valeriani
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Mattia Osti
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Riccardo Maurizi Enrici
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Giuseppe Minniti.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Minniti, G., Scaringi, C., Lanzetta, G. et al. Whole brain reirradiation and concurrent temozolomide in patients with brain metastases. J Neurooncol 118, 329–334 (2014). https://doi.org/10.1007/s11060-014-1435-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11060-014-1435-0

Keywords

  • Brain metastases
  • Temozolomide
  • Whole brain radiation therapy
  • Reirradiation
  • Retreatment